日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 Studies

鲁索替尼乳膏按需单药治疗在轻度至中度特应性皮炎患者中显示出持续的疾病和症状控制：两项3期研究的汇总分析

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-025-01639-0
Blauvelt, Andrew; Kircik, Leon; Simpson, Eric L; Lio, Peter; Eichenfield, Lawrence F; Prajapati, Vimal H; Grewal, Parbeer; Lynde, Charles; Hong, H Chih-Ho; Sturm, Daniel; Kallender, Howard; Ren, Haobo; Paranagama, Dilan; Wong, Grace K W; Geng, Bob
发表日期：2026
文献求助 收藏

Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies

鲁索替尼乳膏单药治疗改善了轻度至中度特应性皮炎成人和青少年患者的症状和生活质量：两项 III 期研究的患者报告结果

期刊:American Journal of Clinical Dermatology
影响因子:8.8
doi:10.1007/s40257-024-00901-z
Simpson, Eric L; Augustin, Matthias; Thaçi, Diamant; Misery, Laurent; Armstrong, April W; Blauvelt, Andrew; Papp, Kim A; Szepietowski, Jacek C; Boguniewicz, Mark; Kwatra, Shawn G; Kallender, Howard; Sturm, Daniel; Ren, Haobo; Kircik, Leon
发表日期：2025
文献求助 收藏

A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic Dermatitis

鲁索替尼乳膏治疗2-11岁中重度特应性皮炎患儿的最大剂量试验

期刊:American Journal of Clinical Dermatology
影响因子:8.8
doi:10.1007/s40257-024-00909-5
Stein Gold, Linda; Bissonnette, Robert; Forman, Seth; Zaenglein, Andrea; Kuo, YuTzu; Angel, Brett; Chen, Xuejun; Kallender, Howard; Paller, Amy S
发表日期：2025
文献求助 收藏

Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies

鲁索替尼乳膏治疗青少年特应性皮炎的疗效、安全性和长期疾病控制：两项随机3期研究的汇总结果

期刊:American Journal of Clinical Dermatology
影响因子:8.8
doi:10.1007/s40257-024-00855-2
Eichenfield, Lawrence F; Simpson, Eric L; Papp, Kim; Szepietowski, Jacek C; Blauvelt, Andrew; Kircik, Leon; Silverberg, Jonathan I; Siegfried, Elaine C; Kuligowski, Michael E; Venturanza, May E; Kallender, Howard; Ren, Haobo; Paller, Amy S
发表日期：2024
文献求助 收藏

Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies

鲁索替尼乳膏用于符合全身治疗严重程度阈值的青少年/成人特应性皮炎患者：两项3期研究汇总结果的探索性分析

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-024-01219-8
Simpson, Eric L; Kircik, Leon; Blauvelt, Andrew; Kallender, Howard; Sturm, Daniel; Wang, Mingyue; Eichenfield, Lawrence F
发表日期：2024
文献求助 收藏

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours

首次人体1期研究，评估精氨酸酶抑制剂INCB001158单药或联合帕博利珠单抗治疗晚期或转移性实体瘤患者的疗效

期刊:
影响因子:
doi:10.1136/bmjonc-2023-000249
Naing, Aung; Papadopoulos, Kyriakos P; Pishvaian, Michael J; Rahma, Osama; Hanna, Glenn J; Garralda, Elena; Saavedra, Omar; Gogov, Sven; Kallender, Howard; Cheng, LuLu; Smith, Michael; Chen, Xuejun; Kuriakose, Emil; Bauer, Todd
发表日期：2024
文献求助 收藏

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

更正：评估口服福瑞替尼（GSK1363089，一种cMET/VEGFR2抑制剂）两种给药方案治疗转移性胃癌患者的II期研究

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0276211
Shah, Manish A; Wainberg, Zev A; Catenacci, Daniel V T; Hochster, Howard S; Ford, James; Kunz, Pamela; Lee, Fa-Chyi; Kallender, Howard; Cecchi, Fabiola; Rabe, Daniel C; Keer, Harold; Martin, Anne-Marie; Liu, Yuan; Gagnon, Robert; Bonate, Peter; Liu, Li; Gilmer, Tona; Bottaro, Donald P
胃癌
肿瘤
肿瘤免疫
EGF
EGFR
VEGF
MET
发表日期：2022
文献求助 收藏

A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia

澳大利亚一项针对晚期或转移性癌症患者的卡瑞利珠单抗首次人体剂量探索研究

期刊:Drug Design Development and Therapy
影响因子:3.5
doi:10.2147/DDDT.S243787
Jason D Lickliter ，Hui K Gan ，Mark Voskoboynik ，Surein Arulananda ，Bo Gao ，Adnan Nagrial ，Peter Grimison ，Michelle Harrison ，Jianjun Zou ，Lianshan Zhang ，Stacey Luo ，Michael Lahn ，Howard Kallender ，Andrea Mannucci ，Catello Somma ，Katherine Woods ，Andreas Behren ，Pablo Fernandez-Penas ，Michael Millward ，Tarek Meniawy
Human
肿瘤
肿瘤免疫
发表日期：2020
文献求助 收藏

A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

一项评估福瑞替尼单药一线治疗晚期肝细胞癌患者的I/II期多中心研究

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-16-1789
Yau, Thomas C C; Lencioni, Riccardo; Sukeepaisarnjaroen, Wattana; Chao, Yee; Yen, Chia-Jui; Lausoontornsiri, Wirote; Chen, Pei-Jer; Sanpajit, Theeranun; Camp, Aaron; Cox, Donna S; Gagnon, Robert C; Liu, Yuan; Raffensperger, Kristen E; Kulkarni, Diptee A; Kallender, Howard; Ottesen, Lone Harild; Poon, Ronnie T P; Bottaro, Donald P
细胞生物学
肿瘤
肿瘤免疫
发表日期：2017
文献求助 收藏

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

II 期研究评估了 cMET/VEGFR2 抑制剂 foretinib (GSK1363089) 口服两种给药方案对转移性胃癌患者的疗效

期刊:PLoS One
影响因子:2.9
doi:10.1371/journal.pone.0054014
Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, Howard S Hochster, James Ford, Pamela Kunz, Fa-Chyi Lee, Howard Kallender, Fabiola Cecchi, Daniel C Rabe, Harold Keer, Anne-Marie Martin, Yuan Liu, Robert Gagnon, Peter Bonate, Li Liu, Tona Gilmer, Donald P Bottaro
肿瘤
胃癌
发表日期：2013
文献求助 收藏